AT 0701

Drug Profile

AT 0701

Alternative Names: Anti influenza monoclonal antibody - AIMM; AT0701

Latest Information Update: 10 May 2017

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator AIMM Therapeutics
  • Developer AIMM Therapeutics; Undisclosed
  • Class Antivirals; Monoclonal antibodies
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Influenza virus infections

Most Recent Events

  • 26 Apr 2017 Phase-II clinical trials in Influenza virus infections in Netherlands (Parenteral) (AIMM Therapeutics pipeline, April 2017)
  • 14 Jan 2014 Anti-influenza monoclonal antibody - AIMM Therapeutics is available for licensing as of 14 Jan 2014.
  • 31 Dec 2013 Phase-I clinical trials in Influenza virus infections in Netherlands (Parenteral)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top